Seattle Genetics gets approval of TUKYSA in Switzerland for metastatic HER2-positive breast cancer

This article was originally published here

The application for TUKYSA approval was reviewed by Swissmedic as part of Project Orbis, an initiative of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence

The post Seattle Genetics gets approval of TUKYSA in Switzerland for metastatic HER2-positive breast cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply